Amgen Science and innovation often start with a bold vision, and Amgen is taking a remarkable step toward shaping the future of biotechnology. The company has announced plans to invest over $600 million to create a cutting-edge science and innovation hub at its worldwide headquarters in Thousand Oaks, California. This move reflects not just an investment in infrastructure but a commitment to advancing medical research, accelerating therapeutic discoveries, and fostering a collaborative ecosystem for scientists and engineers.
Amgen Science and Innovation Hub: A Catalyst for Breakthroughs
The upcoming Amgen science and innovation hub is designed to become a hub of creativity, research, and collaboration. By bringing together experts from diverse fields, this center aims to push the boundaries of medical science. Equipped with advanced automation and digital tools, the facility will provide researchers with state-of-the-art resources to discover therapies for some of the most severe diseases.
Driving Scientific Progress and Biotechnology
Amgen has been a pioneer in biotechnology, and this investment is another milestone in its mission to deliver transformative healthcare solutions. The new hub will not only advance scientific research but also create hundreds of jobs in the United States when construction begins in the third quarter of 2025. It will strengthen Amgen’s global network of facilities, allowing it to harness operational expertise and technological advancements for maximum impact.
A Strong Commitment to US Research and Development
Since the implementation of the Tax Cuts and Jobs Act (TCJA) in 2017, Amgen has invested over $40 billion in manufacturing and research and development. Of this, more than $5 billion has been directed toward direct capital expenditures. The favorable tax environment, further enhanced by the One Big Beautiful Bill Act of 2025, has enabled Amgen to significantly expand its domestic investments in science and manufacturing.
Amgen’s Expanding US Presence
This new announcement adds to a series of major US investments by Amgen, including:
- A $900 million expansion of its Central Ohio manufacturing site.
- A $1 billion investment to build a second manufacturing facility in Holly Springs, North Carolina.
- FDA approval for its Lumakras and Vectibix combination therapy in January 2025 to treat KRAS G12C-mutated metastatic colorectal cancer.
These milestones show how Amgen continues to invest strategically in its infrastructure and scientific capabilities.
How Will the Amgen Science and Innovation Hub Impact the Future?
The Amgen science and innovation hub will serve as a bridge between discovery and delivery. By leveraging automation, advanced research methodologies, and a collaborative workforce, the company will be able to accelerate therapeutic innovations. The center will also play a key role in nurturing scientific talent and fostering partnerships that benefit patients worldwide.
FAQs About the Amgen Science and Innovation Hub
- What is the purpose of the new Amgen hub?
It is designed to accelerate scientific discoveries, promote collaboration, and drive biotechnology research for severe diseases. - Where will the Amgen hub be located?
The hub will be built at Amgen’s worldwide headquarters in Thousand Oaks, California. - How much will Amgen invest in this project?
Amgen will invest over $600 million in constructing the facility. - When will construction start?
Construction is scheduled to begin in the third quarter of 2025. - Will this hub create new jobs?
Yes, it is expected to create hundreds of jobs in the United States. - How does this investment fit into Amgen’s broader strategy?
It complements Amgen’s extensive investments in US research, manufacturing, and infrastructure, which total over $40 billion since 2017.
A Vision for the Future of Science
Amgen’s decision to invest in a new science and innovation hub is more than just a financial move, it is a promise to lead in biotechnology and healthcare innovation. By uniting researchers and leveraging cutting-edge tools, this hub is set to become a launchpad for life-saving therapies and transformative medical breakthroughs.
Disclaimer: This article is based on publicly available information and forward-looking company announcements. Financial figures and timelines are subject to change based on corporate and regulatory developments.
